XGN · XBRL financial data

Exagen financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (XGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	41,975	48,299	45,563	52,548	55,641	66,575
Cost of goods and services sold	16,559	20,588	24,214	23,092	22,529	27,776
Gross profit	—	—	—	29,456	33,112	38,799
Research and development	3,568	7,237	9,876	4,865	5,375	6,254
Selling, general and administrative	37,033	44,541	52,018	47,428	41,373	46,615
Operating income (loss)	(15,185)	(24,067)	(46,051)	(22,837)	(13,636)	(14,070)
Interest income	—	—	—	1,516	767	289
Interest expense	2,565	2,625	2,448	2,335	2,234	4,318
Other income (expense)	984	16	—	—	—	—
Income tax expense (benefit)	(79)	175	(282)	33	12	51
Net income (loss)	(16,687)	(26,851)	(47,387)	(23,689)	(15,115)	(19,951)
Earnings per share, basic USD per share	(1.32)	(1.68)	(2.77)	(1.34)	(0.83)	(0.93)
Earnings per share, diluted USD per share	(1.32)	(1.68)	(2.77)	(1.34)	(0.83)	(0.93)
Weighted average shares, basic thousands of shares	12,633	15,972	17,082	17,679	18,203	21,558
Weighted average shares, diluted thousands of shares	12,633	15,972	17,082	17,679	18,203	21,558

Fiscal years (XGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	57,448	99,442	62,391	36,493	22,036	32,220
Accounts receivable	8,910	9,654	6,077	6,551	7,835	10,855
Prepaid and other current assets	4,159	3,638	4,143	4,797	6,584	5,818
Total current assets	70,517	112,734	72,611	47,841	36,455	48,893
Property and equipment, net	2,102	4,772	8,197	—	—	—
Right-of-use asset	—	0	4,885	3,286	2,401	1,435
Goodwill	5,506	5,506	0	—	—	—
Total assets	78,375	123,445	86,221	56,944	44,689	58,022
Accounts payable	3,014	2,492	3,046	3,131	4,137	4,153
Accrued liabilities	5,757	6,826	5,347	7,531	7,850	6,327
Current portion of long-term debt	—	0	190	264	423	643
Total current liabilities	8,771	9,318	9,623	11,902	13,506	14,159
Long-term debt	26,659	27,478	28,778	19,231	19,822	22,264
Lease liability, non-current	—	0	4,493	2,760	1,664	438
Total liabilities	36,536	38,509	43,761	34,250	35,149	40,573
Accumulated deficit	(181,289)	(208,140)	(255,527)	(279,216)	(294,331)	(314,282)
Total stockholders' equity	41,839	84,936	42,460	22,694	9,540	17,449
Total liabilities and equity	78,375	123,445	86,221	56,944	44,689	58,022
Common shares outstanding (cover page) thousands of shares	12,670	16,231	16,826	17,236	17,898	24,053

Fiscal years (XGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(16,687)	(26,851)	(47,387)	(23,689)	(15,115)	(19,951)
Stock-based compensation	2,694	4,728	4,704	3,617	1,763	2,158
Depreciation and amortization	500	900	1,600	2,200	1,700	2,100
Net cash from operating activities	(14,084)	(20,269)	(32,144)	(14,462)	(13,279)	(13,625)
Purchases of property and equipment	455	2,370	4,318	828	515	641
Net cash from investing activities	(455)	(2,420)	(4,318)	(804)	(515)	(626)
Proceeds from issuing common stock	0	69,144	0	—	0	3,398
Repayments of long-term debt	—	—	0	10,000	0	—
Net cash from financing activities	(97)	64,683	(489)	(10,632)	(663)	24,435
Net change in cash	(14,636)	41,994	(36,951)	(25,898)	(14,457)	10,184

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Exagen	24,588	19,941	3,988*	24.2M	—	Q2 FY26 10-QJun 30, 2026
Freenome	437	not reported	(130)*	not reported	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Fulgent Genetics	26,305	85,389	(23,758)*	27.5M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Sera Prognostics	3,986	42	(7,298)*	not reported	5.9 quarters	Q3 FY26 10-QSep 30, 2026
Fortrea Holdings	220,600	691,500	60,800*	96.5M	—	Q3 FY26 10-QSep 30, 2026
Celcuity	182,049	not reported	(55,426)*	48.9M	13.6 quarters	Q2 FY26 10-QJun 30, 2026
Castle Biosciences	62,116	103,546	15,201*	30.5M	—	Q2 FY26 10-QJun 30, 2026
Personalis	98,271	25,596	(27,072)*	108.4M	6.7 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.